{"id":1627,"date":"2021-09-14T11:00:00","date_gmt":"2021-09-14T11:00:00","guid":{"rendered":"https:\/\/d.ptpl.dev\/acarix\/acarix-begins-us-expansion-and-appoints-us-president\/"},"modified":"2024-08-06T12:25:13","modified_gmt":"2024-08-06T12:25:13","slug":"acarix-begins-us-expansion-and-appoints-us-president","status":"publish","type":"post","link":"https:\/\/d.ptpl.dev\/acarix\/acarix-begins-us-expansion-and-appoints-us-president\/","title":{"rendered":"Acarix begins US expansion and appoints US President"},"content":{"rendered":"
<\/strong><\/div>\n
\n

\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0
Press release
Malm\u00f6, Sweden, September 14, 2021<\/p>\n

Acarix begins US expansion and appoints US President<\/p>\n

Acarix is announcing today that the company has recruited Helen Ljungdahl Round as head of the company\u2019s newly established US subsidiary Acarix Inc. Helen will assume her position in September 2021 to build the US organization. She will be member of Acarix AB\u2019s Group Management.<\/strong><\/p>\n

Helen Ljungdahl Round has over 25 years of experience from senior and global positions such as with the pharmaceutical company Merck & Co, Inc (MSD) and as Senior Vice President of Global Marketing & Business Development for GN Hearing. Helen\u2019s most recent position was as CEO of Amincell, a start-up biotech company based in New York. Helen resides with her family in Pennsylvania, USA and has spent most of her professional life in the US and with American companies, as well as Board appointments and Advisory assignments.<\/p>\n

Per Persson, CEO of Acarix, comments: \u201cWe are delighted to have recruited Helen to lead our new US operations in this intense and exciting phase for Acarix. Helen has a wealth of experience in global sales and marketing in health technology and the pharmaceutical sector. Her background and experience provide us with the right leadership to successfully drive sales of CADScor\u00ae and establish Acarix in the North American market.\u201d <\/em><\/p>\n

Acarix AB\u2019s wholly-owned subsidiary Acarix Inc. was founded in New York. The US Food and Drug Administration (FDA) approved Acarix\u2019s De Novo application for its CADScor\u00ae system at the end of 2020, enabling commercialization in the US market, which the company estimates to have an annual potential in excess of SEK 10 billion.<\/p>\n

For further information, please contact: <\/strong>
Per Persson, CEO, E-mail: per.persson@acarix.com<\/a>, Phone: +46 73 600 59 90<\/p>\n

The information was released for public disclosure, through the <\/em>contact <\/em>person\u2019s<\/em> agency<\/em> above, on <\/em>September <\/em>14<\/em>, 202<\/em>1<\/em>,<\/em> at <\/em>13<\/em>.<\/em>0<\/em>0<\/em> CET.<\/em><\/p>\n

About Acarix:<\/strong>
Acarix was established in 2009 and is listed on Nasdaq First North Premier Growth Market (ticker: ACARIX). Acarix\u2019s CADScor System uses an advanced sensor placed on the skin above the heart to listen to the sounds of cardiac contraction movement and turbulent flow. It has been designed to be an all-in-one system in the sense that the heart signal will be recorded, processed, and displayed as a patient-specific score, the CAD-score, on the device screen. The readout is obtained in less than 10 minutes. Safe and suitable for use in both out- and inpatient settings, the CADScor System thus has the potential to play a major role in patient triage, avoiding the need for many patients to undergo stressful invasive diagnostic procedures. Redeye AB (+46 (0)8 121 576 90, certifiedadviser@redeye.se<\/a>) is Certified Adviser to Acarix. For more information, please visit www.acarix.com<\/a>.<\/p>\n<\/p>\n

\n <\/div>\n

\n

Attachments<\/strong><\/p>\n\n

Acarix_PR_US expansion_ENG<\/a><\/p>\n<\/div>\n

<\/div>\n